Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Trial of OPC-167832 Drug-drug Interactions in Healthy Adults
NCT07542847Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of quabodepistat in Tuberculosis (TB) (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Plasma Concentration at Day 25, Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t at Day 25 and 1 more. Started Sep 2022; status: completed.
02
Drugs
quabodepistat
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07542847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542847.